LONDON-- GlaxoSmithKline PLC (GSK.LN) Wednesday said it has submitted a request to the European Medicines Agency for a variation to the marketing authorization for its anemia treatment eltrombopag after conducting two studies on the treatment.

Shares at 1312 GMT, up 1 pence, or 0.7%, at 1,441 pence valuing the company at GBP70 billion.

-Write to Rory Gallivan at rory.gallivan@wsj.com; Twitter: @RoryGallivan

Subscribe to WSJ: http://online.wsj.com?mod=djnwires

GSK (NYSE:GSK)
Historical Stock Chart
From Mar 2024 to Apr 2024 Click Here for more GSK Charts.
GSK (NYSE:GSK)
Historical Stock Chart
From Apr 2023 to Apr 2024 Click Here for more GSK Charts.